ClinicalTrials.gg
TerminatedNCT00555009Updated Jun 2, 2010Results posted

Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury

A Phase 4 interventional study of Genotropin and Placebo in Brain Injuries and Growth Hormone Deficiency, sponsored by Pfizer. Terminated at 9 sites in 6 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-06-02.

Primary conditionBrain Injuries, TraumaticRegistry: Brain InjuriesReclassifiedWhy we changed it
Registry
Brain Injuries — the first condition term the registry derived for this study.
ClinicalTrials.gg
Brain Injuries, Traumatic
Why
  1. The study's title name Brain Injuries, Traumatic, a narrower term within Brain Injuries.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 98 studies in Brain Injuries, Traumatic with a site in France — 24 open to participants now, 26 under way, 2 of them phase 3. Brain Injuries, Traumatic · France.

Enrollment
60th of 66
10 · median 55
Started
2008
with 5 others
Phase 4
5 of 98
none open now
Registered
5th of 98
by date

Among the 98 studies in Brain Injuries, Traumatic with a site in France, this one is the 60th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2008, is one of 5 in phase 4, and was the 5th registered.

Brain Injuries, Traumatic

1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

24 of the 98 studies in Brain Injuries, Traumatic with a site in France are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 285 Brain Injuries, Traumatic studies recruiting now, 124 (44%) set no upper age limit and 119 (42%) stop at 75 or younger; 40 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Brain Injuries, Traumatic with a site in France, or all of them as a file.
02

Study summary

To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.

Read the detailed description

The study was terminated on 15-Dec-2008 due to an inability to recruit the protocol specified patient population. The study has not been terminated due to any safety concerns.

03

Conditions studied

  • Brain Injuries
  • Growth Hormone Deficiency

Browse trials for

Keywords

  • traumatic brain Injury, cognitive function
04

In context

Brain Injuries, Traumatic Reclassified

1,724 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

This study's enrollment of 10 is below the median of 52 across 1,090 interventional studies indexed under Brain Injuries, Traumatic.

Browse Brain Injuries, Traumatic studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Brain Injuries, Traumatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had a previous traumatic brain injury (more than 1 year and less than 20 years) prior to the screening visit.
  • Have an Extended Glasgow Outcome Scale (GOS-E) more than or equal to 5.
  • Have proven GHD deficiency

Exclusion criteria

Exclusion Criteria:

  • Active systemic or active intracranial tumor. A successfully treated tumor or malignancy is not an exclusion criterion if the patient has not had active disease for 5 years and is not currently receiving maintenance chemotherapy, (except for basal cell skin cancers.
  • Receiving treatment with prednisolone in doses above 10 mg/day or treatment with other oral glucocorticosteroids above replacement doses is not permitted throughout the study. Topical and inhaled are permitted.
  • History of dementia unrelated to TBI
  • History of benign intracranial hypertension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Genotropin treatment arm

    Drug: Genotropin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.

  • DrugPlacebo

    Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in the Cognitive Function (CogState™) Composite Score at Week 36

    CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Change From Baseline in CogState™ at Week 12 and 24.

    CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.

    Time frame: Baseline, Week 12 and 24

  2. Change From Baseline in Lean Body Mass and Fat Mass at Week 36

    The change from Baseline values for lean body mass and fat mass is calculated as the difference between the parameter values at Visit 36, and the parameter values at Baseline.

    Time frame: Baseline, Week 36

  3. Change From Baseline in Neurological Outcome as Assessed by Extended Glasgow Outcome Scale (GOS-E) at Week 36

    The GOS is widely used for assessing outcome after head injury and non-traumatic acute brain insults and is performed by a physician. The GOS-E uses eight points to assess disability and handicap. The GOS-E focuses on how the injury has affected functioning in major areas of life rather than on the particular deficits and symptoms caused by injury. The overall score ranges from 1-8; 1=Death and 8=Upper Good Recovery

    Time frame: Baseline, Week 36

  4. Change From Baseline in Quality of Life Using Short Form (SF)-36 Health Survey at Week 36

    A subject administered scale assessing general quality of life. A subject administered score, scale, direction of scale. The SF-36 consists of 36 questions covering the following eight health domains (subscales): Physical Functioning, Bodily Pain, Role Limitations Due to Physical Problems, Role Limitations Due to Emotional Problems, General Health Perceptions, Mental Health, Social Function, Vitality.

    Time frame: Baseline, Week 36

  5. Change From Baseline In Assessment of Growth Hormone Deficiency in Adults (AGHDA) Questionnaires at Week 36

    The AGHDA is a quality of life subject-administered questionnaire that is condition-specific and comprises of 25 'Yes' or 'No' statements covering 6 dimensions - mobility, pain, energy, sleep, emotional reactions and social isolation. The AGHDA total score change from Baseline values is calculated as the difference between the total score at Visit 6 (Week 36), and the total score at Baseline.

    Time frame: Baseline, Week 36

  6. Change From Baseline in Cardiovascular Risk

    The cardiovascular risk parameters (low-density lipoprotein-cholesterol, high-density lipoprotein cholesterol, total cholesterol and fasting triglycerides) was measured at all visits (Weeks 2, 4, 12, 24, and 36).

    Time frame: Baseline, Weeks 2, 4, 12, 24, and 36

  7. Change From Baseline in Weight

    Time frame: Baseline, Weeks 2, 4, 12, 24, and 36

  8. Change From Baseline in Waist Circumference

    Time frame: Baseline, Weeks 2, 4, 12, 24, and 36

08

Results

Posted Jun 2, 2010

Participant flow

Due to poor recruitment, the study was terminated early; therefore efficacy analyses were not completed.

Participant flow — Overall Study
MilestoneGenotropinPlacebo
Started46
Completed20
Not completed26
Withdrew: Withdrawal by subject01
Withdrew: Terminated by sponsor25

Outcome measures

PrimaryChange From Baseline in the Cognitive Function (CogState™) Composite Score at Week 36

CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.

Time frame:
Baseline, Week 36
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in CogState™ at Week 12 and 24.

CogState™: 7 tasks: Detection (Part A); Identification; One back working memory; Monitoring; One card learning; Prediction; Detection (Part B). Detection, Identification, Monitoring score range: 2 (worse) to 5 (best); One back working memory/one card learning score range: 0 (worse) to 1.57 (best); Prediction score range: 0 (worse) to 100 (best). Composite change score=average of cognitive change scores for each task at each postdrug assessment; total possible score: -300 to 300. Change=change from baseline (average of 2 postdose assessments). Positive composite score=improved performance.

Time frame:
Baseline, Week 12 and 24
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Lean Body Mass and Fat Mass at Week 36

The change from Baseline values for lean body mass and fat mass is calculated as the difference between the parameter values at Visit 36, and the parameter values at Baseline.

Time frame:
Baseline, Week 36
Reported as:
Mean · kg

No measurements were reported for this outcome.

SecondaryChange From Baseline in Neurological Outcome as Assessed by Extended Glasgow Outcome Scale (GOS-E) at Week 36

The GOS is widely used for assessing outcome after head injury and non-traumatic acute brain insults and is performed by a physician. The GOS-E uses eight points to assess disability and handicap. The GOS-E focuses on how the injury has affected functioning in major areas of life rather than on the particular deficits and symptoms caused by injury. The overall score ranges from 1-8; 1=Death and 8=Upper Good Recovery

Time frame:
Baseline, Week 36
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Quality of Life Using Short Form (SF)-36 Health Survey at Week 36

A subject administered scale assessing general quality of life. A subject administered score, scale, direction of scale. The SF-36 consists of 36 questions covering the following eight health domains (subscales): Physical Functioning, Bodily Pain, Role Limitations Due to Physical Problems, Role Limitations Due to Emotional Problems, General Health Perceptions, Mental Health, Social Function, Vitality.

Time frame:
Baseline, Week 36
Reported as:
Mean · score on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline In Assessment of Growth Hormone Deficiency in Adults (AGHDA) Questionnaires at Week 36

The AGHDA is a quality of life subject-administered questionnaire that is condition-specific and comprises of 25 'Yes' or 'No' statements covering 6 dimensions - mobility, pain, energy, sleep, emotional reactions and social isolation. The AGHDA total score change from Baseline values is calculated as the difference between the total score at Visit 6 (Week 36), and the total score at Baseline.

Time frame:
Baseline, Week 36
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cardiovascular Risk

The cardiovascular risk parameters (low-density lipoprotein-cholesterol, high-density lipoprotein cholesterol, total cholesterol and fasting triglycerides) was measured at all visits (Weeks 2, 4, 12, 24, and 36).

Time frame:
Baseline, Weeks 2, 4, 12, 24, and 36
Reported as:
Mean · scores on a scale

No measurements were reported for this outcome.

SecondaryChange From Baseline in Weight
Time frame:
Baseline, Weeks 2, 4, 12, 24, and 36
Reported as:
Mean · kg

No measurements were reported for this outcome.

SecondaryChange From Baseline in Waist Circumference
Time frame:
Baseline, Weeks 2, 4, 12, 24, and 36
Reported as:
Mean · cm

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotropin—0/4 (0%)4/4 (100%)
Placebo—0/6 (0%)0/6 (0%)
Most frequent other events
Most frequent other events
EventGenotropinPlacebo
PyrexiaGeneral disorders1/40/6
Lower limb fractureInjury, poisoning and procedural complications1/40/6
ArthralgiaMusculoskeletal and connective tissue disorders1/40/6
SomnolenceNervous system disorders1/40/6

Baseline characteristics

Age, Customized
Age, Customized(participants)GenotropinPlaceboTotal
<18 years000
18 - 44 years448
45-64 years022
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)GenotropinPlaceboTotal
Female000
Male4610
09

Study locations

9 sites
  • Pfizer Investigational Site
    Creteil Cedex, 94010, France
  • Pfizer Investigational Site
    Paris Cedex 13, 75651, France
  • Pfizer Investigational Site
    Ferrara, 44100, Italy
  • Pfizer Investigational Site
    Roma, 00168, Italy
  • Pfizer Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • Pfizer Investigational Site
    Sevilla, 41013, Spain
  • Pfizer Investigational Site
    Göteborg, 413 45, Sweden
  • Pfizer Investigational Site
    Stockholm, 171 76, Sweden
  • Pfizer Investigational Site
    Salford, Manchester M6 8HD, United Kingdom
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2007
First posted
Nov 7, 2007
Start
Mar 2008
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results first posted
Jun 2, 2010
Last update
Jun 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00555009
Lead sponsor
Pfizer
First posted
Nov 7, 2007
Start date
Mar 2008
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Jun 2, 2010
Last update
Jun 2, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion